LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

1.78 -2.2

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.76

Max

1.85

Chiffres clés
By Trading Economics
Revenu	-3.8M -43M
BPA	-0.18
Employés	150
EBITDA	-3.9M -43M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+378.57% upside

Dividendes
By Acuity
Prochains Résultats	12 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-138M 649M
Ouverture précédente	3.98
Clôture précédente	1.78

Sentiment de l'Actualité

By Acuity

34%

66%

87 / 344 Classement par Healthcare

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 juin 2026, 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

10 juin 2026, 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 juin 2026, 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 juin 2026, 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 juin 2026, 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

10 juin 2026, 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

10 juin 2026, 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 juin 2026, 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 juin 2026, 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 juin 2026, 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 juin 2026, 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 juin 2026, 23:38 UTC

Global Equities Roundup: Market Talk

10 juin 2026, 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

10 juin 2026, 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 juin 2026, 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 juin 2026, 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 juin 2026, 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

10 juin 2026, 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 juin 2026, 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

10 juin 2026, 20:50 UTC

Financial Services Roundup: Market Talk

10 juin 2026, 20:50 UTC

Basic Materials Roundup: Market Talk

10 juin 2026, 20:50 UTC

Health Care Roundup: Market Talk

10 juin 2026, 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 juin 2026, 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 juin 2026, 20:33 UTC

Global Equities Roundup: Market Talk

10 juin 2026, 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

378.57% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 378.57%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

87 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.